No Data
US Stock MarketDetailed Quotes
PSTV Plus Therapeutics
Watchlist
3.7600
-0.1400-3.59% Close 06/06 16:00 ET
3.76000.00000.00%
Post 16:00 ET
3.9800High3.6800Low18.43KVolume
3.9800Open3.9000Pre Close70.14KTurnover0.74%Turnover RatioLossP/E (TTM)9.37MMarket Cap18.000052wk HighLossP/E (Static)2.49MShares3.210052wk Low3.50P/B9.33MFloat Cap7507.4985Historical High--Dividend TTM2.48MShs Float3.2100Historical Low--Div YieldTTM7.69%Amplitude3.8060Avg Price1Lot Size
Post-Market
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Company
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The firm focuses on the development of chemotherapeutics and radio therapeutics for rare cancers that address unmet medical and market needs. Its products include Rhenium NanoLiposome and DocePLUS. The company was founded by Ralph E. Holmes and Christopher J. Calhoun in July 1996 and is headquartered in Austin, TX.
Revenue Breakdown
Business
Unit:USD
NameYOYOperating income%
Single segment--224K100.00%
News
Plus Therapeutics Provides Company Update Today
Presentation at 2023 Virtual June Investor Summit to highlight clinical development progressAUSTIN, Texas, June 01, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a
Plus Therapeutics Announces Topline Results From Recurrent Glioblastoma External Control Analysis at ASCO 2023
Plus Therapeutics' partnership with Medidata resulted in a valid historical control arm for the Company's Phase 1/2 clinical and potential Phase 3 trials evaluating rhenium (186Re) obisbemeda in recurrent glioblastoma
Plus Therapeutics to Present at the 2023 Virtual June Investor Summit
AUSTIN, Texas, May 25, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies
Comments
$Plus Therapeutics(PSTV.US$ Nice He's giving an Update
$Plus Therapeutics(PSTV.US$ Long play. Hold
1
$Plus Therapeutics(PSTV.US$ Buy and Hold
1
2
Read more